{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=7", "query": { "condition": "Bladder Cancer Recurrence", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Recurrence&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T03:00:01.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003704", "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "1999-04", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003704" }, { "nct_id": "NCT00030615", "title": "Decitabine in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Melanoma", "Stage III Melanoma", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Melanoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030615" }, { "nct_id": "NCT04149574", "title": "A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "nivolumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Bacillus Calmette-Guérin (BCG)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2020-01-15", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 2, "location_summary": "Chicago, Illinois • The Bronx, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04149574" }, { "nct_id": "NCT00006124", "title": "Celecoxib in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Bladder Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2000-06", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2013-02-13", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006124" }, { "nct_id": "NCT00661609", "title": "A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Bladder Cancer", "Urethra Cancer", "Ureter Cancer", "Renal Pelvis Cancer" ], "interventions": [ { "name": "AZD4877", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2008-05", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2011-01-12", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 18, "location_summary": "Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661609" }, { "nct_id": "NCT00365157", "title": "Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2006-10-23", "completion_date": "2027-07-09", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 26, "location_summary": "Beverly Hills, California • Duarte, California • Lancaster, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Martinez", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365157" }, { "nct_id": "NCT01478685", "title": "A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms", "Carcinoma, Transitional Cell", "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Pancreatic Ductal", "Tumor Virus Infections" ], "interventions": [ { "name": "CC-486", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "ABI-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2011-11-29", "completion_date": "2015-11-17", "has_results": false, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478685" }, { "nct_id": "NCT00055835", "title": "S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Urethral Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2002-11", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 92, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055835" }, { "nct_id": "NCT05508568", "title": "A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "ADXBLADDER", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Arquer Diagnostics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 650, "start_date": "2021-07-01", "completion_date": "2023-04", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 13, "location_summary": "Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Troy", "state": "Michigan" }, { "city": "Mount Laurel", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05508568" }, { "nct_id": "NCT02646319", "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Cervical Squamous Cell Carcinoma", "Endometrial Carcinoma", "Malignant Uterine Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage III Bladder Cancer", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Ovarian Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Bladder Cancer", "Stage IVA Cervical Cancer", "Stage IVB Bladder Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nanoparticle Albumin-Bound Rapamycin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-01", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-11-01T03:00:01.714Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646319" } ] }